Gout | More than Flares
Dr. John Cush Tweet
@RheumNow
When Gout Flares, So Does the Cardiovascular System We have spent decades teaching that a gout flare is a joint problem: a hot, swollen, painful joint that we treat with anti-inflammatory drugs and move on from (i.e., the treat to avoid symptoms strategy). The campaign title https://t.co/HCUQVaor4f
Dr. John Cush Tweet
@RheumNow
2 T2T RCTs of 383 gout pts starting allopurinol - 31% had tophi. At 12 mos achieving target uric acid (<0.36mmol/L) was same in pts with and without tophi (70.3 vs 73.6), as was the %gout flares in month 11 (71.4% vs 79.7%; p=0.21). Allopurinol T2T success not influenced by https://t.co/zr7K8Y2Bqz
Dr. John Cush Tweet
@RheumNow
Evidence-Based Dietary Recommendations for Gout Gout, historically referred to as the “disease of kings,” was once associated with a lifestyle of excess. Today, it is more appropriate to refer to gout as a “disease of commoners,” as it is the most common inflammatory arthritis https://t.co/uIrSeOjxJZ
Dr. John Cush Tweet
@RheumNow
Pragmatism in Gout: How therapeutic choices can have multiple benefits Drugs prescribed to calm flares or lower uric acid are designed with one primary goal in mind, yet many also produce meaningful effects beyond the joints. Some of those secondary effects are unwelcome; such https://t.co/QvXAwFM7LJ
Dr. John Cush Tweet
@RheumNow
UK primary care database (2000–21) gout study of new colchicine initiators (n 31,478) vs noninitiators (mean 60 yrs, BMI 30), follow-up of 4.5 yrs. Colchicine use had a signif. 12% lower risk of Joint Arthroplasty (HR 0.88); 23% lower TJA in knee/hip OA (HR 0.77) https://t.co/bT07lUYBB2
Dr. John Cush Tweet
@RheumNow
"Leeuwenhoek (invented the microscope) examined uric acid (C5H4N4O3) crystals from gout patients and found them to resemble needles. He expounded on his observations in an 11 July 1679 letter responding to an earlier query from Mr. Lambert van Velthuysen (1622–1685), a physician, https://t.co/mY2wqYlRda
Dr. John Cush Tweet
@RheumNow
UK primary care database (2000–21) gout study of new colchicine initiators (n 31,478) vs noninitiators (mean 60 yrs, BMI 30), follow-up of 4.5 yrs. Colchicine use had a signif. 12% lower risk of Joint Arthroplasty (HR 0.88); 23% lower TJA in knee/hip OA (HR 0.77) https://t.co/TkYFYhANuH
Article

Evidence-Based Dietary Recommendations for Gout

Chio Yokose, MD, MSC

Gout, historically referred to as the “disease of kings,” was once associated with a lifestyle of excess, including ready access to alcohol and rich meats once reserved for society’s highest ranks. Today, it is more appropriate to refer to gout as a “disease of commoners,” as it is

Dr. John Cush Tweet
@RheumNow
The Marriage between Gout and the Kidney While the link between uric acid and gout was first described by Alfred Baring Garrod in the 1800s, the proof that uric acid might actually be the cause had to await the self-experimentation of two rheumatologists from the University of https://t.co/AWZbjaUtdu
Dr. John Cush Tweet
@RheumNow
SGLT2i use in gout reduces use of gout meds. Study of 26,739 gout pts w/ NIDDM (mean 66 yrs), 67% w/ polypharmacy. SGLT2i (vs DPP-4i) user had less Allopurinol starts (HR 0.62;0.52–0.73), also lower use of steroids (,78), NSAID (.85), colchicine (.87) & diuretics (.87) https://t.co/1dW27YzSvg

Therapeutic Updates

Systemic Burden of Gout

Dr. Mark Fisher
Watch our 'Systemic Burden of Gout' series as part of this month's Gout More than Flares campaign. Videos include: Gout Management in Patients with CKD, Gout and CVD, and Gout & Obesity.
Read Post

Campaign Videos

Podcasts

  • TU: Systemic Burden of Gout Part 2 (24 plus)
  • Gout Lessons from the Clinic Part 3
  • Systemic Burden of Gout Part 1
×